How Breo Ellipta Works in the Lungs
Breo Ellipta combines two active ingredients—fluticasone furoate, a corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist (LABA)—delivered via dry powder inhalation. Fluticasone furoate reduces inflammation by binding to glucocorticoid receptors in lung cells, inhibiting inflammatory mediators like cytokines and prostaglandins, which decreases airway swelling, mucus production, and immune cell recruitment.[1] Vilanterol activates beta2 receptors on airway smooth muscle cells, triggering cyclic AMP elevation that relaxes muscles and prevents bronchoconstriction.[1][2]
Why the Combination Targets COPD and Asthma
The duo provides complementary effects: the corticosteroid handles underlying inflammation, while the LABA offers rapid, sustained bronchodilation lasting 24 hours. This dual action improves lung function (measured by FEV1) more than either alone in chronic obstructive pulmonary disease (COPD) and asthma maintenance therapy.[1][3]
How Long Effects Last and Dosing Schedule
One daily inhalation suffices due to vilanterol's 22+ hour bronchodilation and fluticasone's prolonged lung retention. Peak effects occur within 5-15 minutes for vilanterol and hours for anti-inflammatory benefits.[1][2]
Common Side Effects Tied to Mechanism
LABA action raises risks of tachycardia, tremor, or hypokalemia from beta2 stimulation; corticosteroid effects include oral candidiasis, dysphonia, or pneumonia in COPD patients from local immunosuppression.[1][3]
How It Differs from Single-Agent Inhalers
Unlike short-acting beta agonists (e.g., albuterol) for rescue, Breo is for maintenance only—LABA monotherapy risks asthma exacerbations. It outperforms ICS-only inhalers (e.g., Flovent) in preventing severe COPD flares.[3]
[1]: Breo Ellipta Prescribing Information (GSK)
[2]: DrugPatentWatch.com - Vilanterol Mechanism
[3]: FDA Label for Breo Ellipta